Cardiac Biotech Solutions, Inc. (CBSC) Signs Exclusive 5-Year Distribution Agreement with Noventis Medical Covering Costa Rica, Panama, Colombia, and Argentina
Cardiac Biotech Solutions (OTCID: CBSC) has secured a five-year exclusive distribution agreement with Noventis Medical for its cardiac monitoring products in Costa Rica, Panama, Colombia, and Argentina. The contract is valued at $600,000 USD and includes a right of first refusal for future distribution opportunities in other Central and South American countries.
The agreement centers on CBSC's MyCardia AT event monitoring platform, which combines wearable technology with AWS Cloud connectivity and mobile applications. The company has already obtained regulatory clearance in the U.S. and is pursuing additional approvals in Canada and China as part of its global expansion strategy.
Cardiac Biotech Solutions (OTCID: CBSC) ha firmato un accordo di distribuzione esclusiva di cinque anni con Noventis Medical per i suoi prodotti di monitoraggio cardiaco in Costa Rica, Panama, Colombia e Argentina. Il contratto ha un valore di 600.000 USD e include un diritto di prelazione per future opportunità di distribuzione in altri Paesi dell'America Centrale e del Sud.
L'intesa riguarda la piattaforma di monitoraggio per eventi MyCardia AT di CBSC, che integra tecnologia indossabile con connettività AWS Cloud e applicazioni mobili. L'azienda ha già ottenuto l'autorizzazione normativa negli Stati Uniti e sta perseguendo approvazioni aggiuntive in Canada e Cina come parte della sua strategia di espansione globale.
Cardiac Biotech Solutions (OTCID: CBSC) ha cerrado un acuerdo de distribución exclusiva por cinco años con Noventis Medical para sus productos de monitoreo cardíaco en Costa Rica, Panamá, Colombia y Argentina. El contrato está valorado en 600.000 USD e incluye un derecho de tanteo para futuras oportunidades de distribución en otros países de Centro y Suramérica.
El acuerdo se centra en la plataforma de monitoreo de eventos MyCardia AT de CBSC, que combina tecnología wearable con conectividad AWS Cloud y aplicaciones móviles. La compañía ya cuenta con la autorización regulatoria en EE. UU. y está gestionando aprobaciones adicionales en Canadá y China como parte de su estrategia de expansión global.
Cardiac Biotech Solutions (OTCID: CBSC)는 Noventis Medical과 5년간의 독점 유통 계약을 체결하여 코스타리카, 파나마, 콜롬비아, 아르헨티나에서 심장 모니터링 제품을 공급하게 되었습니다. 해당 계약의 가치는 600,000 USD이며, 중남미 다른 국가에서의 향후 유통 기회에 대한 우선거래권을 포함합니다.
이번 계약은 웨어러블 기술과 AWS 클라우드 연결 및 모바일 애플리케이션을 결합한 CBSC의 이벤트 모니터링 플랫폼 MyCardia AT를 중심으로 합니다. 회사는 이미 미국에서 규제 승인 을 받았으며, 글로벌 확장 전략의 일환으로 캐나다와 중국에서의 추가 승인을 추진하고 있습니다.
Cardiac Biotech Solutions (OTCID: CBSC) a conclu un accord de distribution exclusive de cinq ans avec Noventis Medical pour ses produits de surveillance cardiaque au Costa Rica, au Panama, en Colombie et en Argentine. Le contrat est évalué à 600 000 USD et inclut un droit de premier refus pour de futures opportunités de distribution dans d'autres pays d'Amérique centrale et d'Amérique du Sud.
L'accord porte sur la plateforme de surveillance d'événements MyCardia AT de CBSC, qui associe une technologie portable à la connectivité AWS Cloud et à des applications mobiles. La société a déjà obtenu l'autorisation réglementaire aux États-Unis et poursuit des approbations supplémentaires au Canada et en Chine dans le cadre de sa stratégie d'expansion mondiale.
Cardiac Biotech Solutions (OTCID: CBSC) hat eine fünfjährige Exklusivvertriebsvereinbarung mit Noventis Medical für seine Herzüberwachungsprodukte in Costa Rica, Panama, Kolumbien und Argentinien abgeschlossen. Der Vertrag hat einen Wert von 600.000 USD und enthält ein Vorkaufsrecht für künftige Vertriebsgelegenheiten in anderen Ländern Zentral- und Südamerikas.
Gegenstand der Vereinbarung ist die Ereignisüberwachungsplattform MyCardia AT von CBSC, die Wearable-Technologie mit AWS-Cloud-Konnektivität und mobilen Anwendungen verbindet. Das Unternehmen hat bereits die Zulassung in den USA erhalten und strebt im Rahmen seiner globalen Expansionsstrategie weitere Genehmigungen in Kanada und China an.
- Secured $600,000 USD distribution agreement for Latin American markets
- Obtained exclusive distribution rights in four key countries for 5 years
- Right of first refusal for additional Central and South American markets
- Product already has U.S. regulatory clearance with Canada and China submissions in progress
- None.
LAS VEGAS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced the execution of a new distribution agreement with Noventis Medical, granting the Company five-year exclusive rights to distribute CBSC’s products across Costa Rica, Panama, Colombia, and Argentina.
Under the terms of the agreement, Noventis Medical has committed to a total of
“We are delighted to expand our international presence through this new strategic partnership with Noventis Medical,” said Charles Martin, Chief Executive Officer of CBSC. “This agreement strengthens our reach into key Latin American markets and, we believe, provides a solid foundation for additional regional expansion. We also believe that the right of first refusal provision also ensures that our long-term collaboration with Noventis can grow in step with future opportunities across Central and South America.”
John Quam, President of Noventis Medical stated, “Noventis Medical is very excited to collaborate with CBSC and its product, MyCardia AT, to bring a reliable solution for identifying heart issues in the Latin American market. Cardiovascular disease remains the leading cause of death in the region, and this technology provides doctors with early insights so they can address problems and keep patients healthier for longer. We are committed to working alongside the medical community to deliver innovative tools that truly make a difference.”
The Company continues to advance global commercialization of its MyCardia AT event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the U.S. and additional submissions progressing in Canada and China, CBSC’s newest international agreement represents another milestone in its mission to provide state-of-the-art cardiac monitoring solutions worldwide.
As additional new developments occur, Cardiac Biotech Solutions, Inc. will make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
About Cardiac Biotech Solutions, Inc.:
Cardiac Biotech Solutions, Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Investor Inquiries: investor@cardiacbiotech.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
FAQ
What is the value of CBSC's distribution agreement with Noventis Medical?
Which countries are included in CBSC's new distribution agreement?
What is MyCardia AT and where has it received regulatory approval?
What special rights does Noventis Medical have for future CBSC distribution opportunities?
How long is CBSC's distribution agreement with Noventis Medical?
